David J. Mazzo, PhD
President and Chief Executive Officer
Dr. Mazzo is a seasoned public and private company director having served on the boards of all the companies for which he was CEO plus Essex Chimie AG (EU subsidiary of Schering-Plough), Avanir Pharmaceuticals, EyePoint Pharmaceuticals and Seneca Biopharma. For Avanir (NASDAQ: AVNR), he served from 2005 – 2015 (until the sale of Avanir to Otsuka) and was, at various times, a member of the Executive committee of the Board, Science committee, Audit committee and/or Governance committee. From 2008 to 2015, he served as chairman of the Compensation committee. For EyePoint (NASDAQ: EYPT), Dr. Mazzo has also served since 2005 and has been, at various times, a member of the Science, Audit and/or Governance committees. He has chaired the Compensation committee since 2005 and was Chairman of the Board from 2007 - 2018. For Seneca (NASDAQ: SNCA), Dr. Mazzo has served since 2019. He is a member both the Compensation and Nominating & Governance Committees.
Dr. Mazzo has spent his entire career within the pharmaceutical industry, rising quickly from the laboratory to occupy positions of increasing executive responsibility with Merck, Baxter, Rhône-Poulenc Rorer, Hoechst Marion Roussel and Schering-Plough before becoming CEO of Chugai USA (private) followed by Aeterna Zentaris (public), Regado Biosciences (which he took public) and Caladrius Biosciences (public). The diversity of his assignments has resulted in an expertise across all therapeutic areas as well as the whole of the drug development process from Discovery to Development to Product Commercialization.
Dr. Mazzo earned his Ph.D. in Analytical Chemistry as well as an M.S. in Chemistry at the University of Massachusetts (Amherst). He also holds dual degrees [B.S. in Chemistry and B.A. in Honors (Interdisciplinary Humanities)] from Villanova University. He complemented his American education as a Research Fellow at the Ecole Polytechnique Fédérale de Lausanne in Switzerland.
Douglas W. Losordo, MD, FACC, FAHA
Executive Vice President, Global Head of Research and Development, Chief Medical Officer
Dr. Losordo has engaged in career-long efforts to develop regenerative medicine therapeutics. As a scientist he obtained over $35 million in National Institutes of Health funding, for discovering and developing new therapeutic concepts in the laboratory, providing the basis for clinical studies. He has led first in human studies in multiple gene and adult stem cell therapies in patients with cardiovascular diseases, including therapies now in Phase 3 testing. He is a highly sought after speaker, having given over 200 international lectures. He has served as an associate editor of Circulation Research, the basic science journal of the American Heart Association and serves on the editorial boards of a number of scientific journals.
Todd Girolamo, JD
Senior Vice President, General Counsel and Corporate Secretary
Mr. Girolamo began his legal career as an associate at Cahill Gordon & Reindel, and he concluded his tenure in private practice at Reid & Priest, where he gained expertise as a general commercial litigator practicing in the areas of intellectual property, securities law, employment law and bankruptcy. In addition to over a decade of experience as both corporate counsel and private practitioner, Mr. Girolamo spent 12 years on Wall Street where he specialized in therapeutic healthcare equity securities at Oppenheimer & Co., CIBC World Markets, Leerink Swann & Company and Summer Street Research Partners.
Mr. Girolamo received a Bachelor of Arts from Harvard College, Juris Doctor from the University of Pennsylvania Law School and Master of Business Administration from Columbia Business School.
Vice President, Human Resources
Ms. Holler's background includes developing and leading global teams. She has driven organizational transformation efforts at Innophos Inc., a global specialty chemical company as VP of HR where she planned and developed organizational design and integration activity for mergers and acquisitions. In addition, she served as management liaison to the Compensation and Nominating and Governance Committees. Prior to Innophos, Ms. Holler served as Director of Organizational Effectiveness at Tata Consultancy Services where she was responsible for on-boarding, training and deployment of talent for the organization. Prior to that, Ms. Holler served as VP of HR at LifeCell Corporation where she established the HR organization and led the growth of the organization through succession planning, career development and recruitment of key talent. Prior to joining LifeCell, she was with Sanofi Aventis (and legacy companies) for 14 years where she held increasingly more responsible positions in global HR generalist capacities including HR Director for Global Drug Development and VP of HR, Global Dermatology.
Ms. Holler received a BA from the University of Delaware.
Gregory S. Berkin
Vice President of IT and Cybersecurity and Chief Information Officer
Greg Berkin joined Caladrius in January 2015. Since that time, Greg has been responsible for transforming external IT support into an internal team working as a highly-efficient operating unit across all five Caladrius and PCT sites. He also manages all groups within IT: Networking, PC, Cybersecurity, Applications, Business Solutions, and Telecom.
Before joining Caladrius, Greg held director and management roles in IT at other biotech companies including Regado Biosciences, Aeterna Zentaris, and Chugai Pharma USA.
Greg has 25 years in the technical profession with 20 years of unparalleled managerial experience, specializing in production systems, network engineering, facility operations, project management, hybrid cloud-computing, cybersecurity, and M&A activities.
John D. Menditto
Vice President, Investor Relations and Corporate Communications
Mr. Menditto has over 25 years of experience and specialization, particularly, in the areas of financial modeling, Regulation FD, corporate governance, investor targeting and capital raising. He has held senior roles at several healthcare and life science companies including Novartis Corporation, Medco Health Solutions and Argos Therapeutics. John has also spent a number of years as a senior communications consultant with The Imagination Group, Makovsky & Co. and MWWPR.
John is a former IR Magazine and PRSA/Big Apple award winner for his work in investor and corporate communications. He holds degrees in public relations and finance from Susquehanna University in Selinsgrove, Pennsylvania.